Ascendis Pharma logo
A71 logo

Ascendis PharmaDB:A71 Stock Report

Market Cap €8.2b
Share Price
n/a
1Y-4.2%
7D20.0%
Portfolio Value
View

A71 Stock Overview

A biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. More details

A71 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Ascendis Pharma A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ascendis Pharma
Historical stock prices
Current Share PriceUS$138.00
52 Week HighUS$147.00
52 Week LowUS$99.00
Beta0.64
1 Month Change7.81%
3 Month Change16.95%
1 Year Change-4.17%
3 Year Change41.54%
5 Year Change14.05%
Change since IPO725.21%

Recent News & Updates

Recent updates

Shareholder Returns

A71DE BiotechsDE Market
7D20.0%-11.3%3.0%
1Y-4.2%-15.0%19.3%

Return vs Industry: A71 exceeded the German Biotechs industry which returned -16.5% over the past year.

Return vs Market: A71 underperformed the German Market which returned 18.5% over the past year.

Price Volatility

Is A71's price volatile compared to industry and market?
A71 volatility
A71 Average Weekly Movement7.0%
Biotechs Industry Average Movement8.4%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.4%
10% least volatile stocks in DE Market2.5%

Stable Share Price: A71 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: A71's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20061,017Jan Mikkelsenascendispharma.com

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Ascendis Pharma A/S Fundamentals Summary

How do Ascendis Pharma's earnings and revenue compare to its market cap?
A71 fundamental statistics
Market cap€8.25b
Earnings (TTM)-€378.08m
Revenue (TTM)€363.64m

24.6x

P/S Ratio

-23.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A71 income statement (TTM)
Revenue€363.64m
Cost of Revenue€44.26m
Gross Profit€319.38m
Other Expenses€697.47m
Earnings-€378.08m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-6.32
Gross Margin87.83%
Net Profit Margin-103.97%
Debt/Equity Ratio-722.4%

How did A71 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/18 20:19
End of Day Share Price 2025/02/18 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascendis Pharma A/S is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Michelle GilsonCanaccord Genuity
Alethia YoungCantor Fitzgerald & Co.